Yeztugo PrEP Injections in NYC and Long Island

Yeztugo is lenacapavir for prevention of sexually acquired HIV-1 in people who do not have HIV. Treatment starts with injections and tablets, then continues with injections about every six months. It can suit someone who prefers fewer medication visits, provided testing and follow-up remain reliable. Twice-yearly medication does not mean twice-yearly attention to every health concern: a new exposure, symptoms, STI screening or a medication change can require contact sooner.

The approved PrEP indication is for adults and adolescents weighing at least 35 kg who are at risk of acquiring HIV through sex. HIV-negative status must be established. Recent exposure, acute viral symptoms, past PrEP/PEP, pregnancy or breastfeeding and all current medicines belong in the evaluation. HIV testing is required before starting and before each injection. A positive or unknown HIV status prevents use as PrEP.

At initiation, a negative antigen/antibody test is confirmed with HIV RNA testing, even if RNA returns after treatment starts. Before continuation, a negative rapid antigen/antibody test requires confirmation with a more sensitive assay. The clinician determines the complete testing approach and reviews symptoms and any ambiguous results.

Provide every prescription, over-the-counter medicine and supplement. Some strong or moderate CYP3A inducers require additional clinician-directed dosing under the August 2026 label; other starting combinations have no recommended regimen. Your prescriber must review the actual medicines and sequence.

The labeled start includes two subcutaneous injections and oral tablets on the first day, followed by oral tablets the next day. Those tablets are part of required initiation, not an optional tolerability trial. A trained professional administers the injections.

Continuation injections are scheduled every 26 weeks with a two-week allowance on either side. Agree on HIV testing, STI screening and what to do before travel or an access delay.

Bring previous HIV and STI results, your current prevention regimen, last injection date if applicable and insurance information. Ask how the next-day tablets will be obtained and how to contact the team if you cannot take them. Confirm medication receipt and testing arrangements before an administration visit. The label describes abdominal injections and an alternative thigh site. The administrator chooses an appropriate site using the current instructions.

YEZTUGO care begins with an HIV-prevention assessment and required testing. Arrange the initiation tablets, administering appointment and subsequent injection dates with the PrEP team. Contact the clinic about medication delivery before traveling; approval of the medicine does not mean every clinic stores a dose for walk-in use.

The boxed warning concerns resistance if Yeztugo is used during undetected HIV. Report possible acute HIV symptoms immediately rather than waiting for a routine dose. Injection pain, swelling or nodules can occur; some nodules last a long time. Seek urgent care for severe allergic symptoms or a rapidly worsening injection-site reaction. Lenacapavir can affect other medicines long after the last injection, so tell future prescribers when you received it.

Call before an injection is overdue. An authorized oral bridge may be used for some planned delays, but the tablets are not a patient-designed substitute for injections. Longer gaps without bridging can require repeating initiation after reassessment. After stopping, residual drug may remain for 12 months or longer. Your clinician plans ongoing HIV testing and alternative prevention while levels decline.

Switching from Apretude or oral PrEP to Yeztugo may be possible after clinical review. It is not an automatic exchange. Tell the PrEP clinician the current regimen, adherence, last tablet or injection date, recent exposure, HIV results and other medicines. The clinician must confirm HIV-negative status, assess possible acute HIV and provide a dated transition plan so protection is not assumed during a gap. Yeztugo initiation requires two injections plus two 300-mg tablets on Day 1, then two 300-mg tablets on Day 2. Its continuation injections are every 26 weeks, with a two-week window either side. That schedule is different from its residual-drug tail: lenacapavir can remain for 12 months or longer, which does not establish continuing protection. After stopping Yeztugo, people with continuing risk need an alternative PrEP plan initiated within 28 weeks of the last injection. Confirm tablets, the administering site and actual appointment before changing the current regimen.

Call before an injection is overdue. An authorized oral bridge may be used for some planned delays, but the tablets are not a patient-designed substitute for injections. Longer gaps without bridging can require repeating initiation after reassessment. After stopping, residual drug may remain for 12 months or longer. Your clinician plans ongoing HIV testing and alternative prevention while levels decline.

At initiation, a negative antigen/antibody test is confirmed with HIV RNA testing, even if RNA returns after treatment starts. Before continuation, a negative rapid antigen/antibody test requires confirmation with a more sensitive assay. The clinician determines the complete testing approach and reviews symptoms and any ambiguous results.

Provide every prescription, over-the-counter medicine and supplement. Some strong or moderate CYP3A inducers require additional clinician-directed dosing under the August 2026 label; other starting combinations have no recommended regimen. Your prescriber must review the actual medicines and sequence.

The labeled start includes two subcutaneous injections and oral tablets on the first day, followed by oral tablets the next day. Those tablets are part of required initiation, not an optional tolerability trial. A trained professional administers the injections.

Continuation injections are scheduled every 26 weeks with a two-week allowance on either side. Agree on HIV testing, STI screening and what to do before travel or an access delay.

Lenacapavir blocks several stages of HIV replication by acting on the viral capsid. Yeztugo is the prevention product. Sunlenca contains the same active medicine but is used with other antiretrovirals for selected people with HIV whose prior treatments have not worked. The brands and care pathways are not interchangeable. Yeztugo alone must not be used as HIV treatment.

The approved PrEP indication is for adults and adolescents weighing at least 35 kg who are at risk of acquiring HIV through sex. HIV-negative status must be established. Recent exposure, acute viral symptoms, past PrEP/PEP, pregnancy or breastfeeding and all current medicines belong in the evaluation. HIV testing is required before starting and before each injection. A positive or unknown HIV status prevents use as PrEP.

Have your insurance card ready when booking. Share member details through the clinic’s confirmed secure intake process. Check with the clinic and your insurer that the exact plan covers the clinician and requested service. Ask about visit charges, any separately billed tests or medicines, and any referral or authorization requirement. Coverage and your copay or deductible depend on the plan; request a written estimate if paying yourself.

No. Oral tablets on both initiation days are part of the labeled regimen. Contact your clinician immediately if the second-day tablets are unavailable, missed or vomited; do not improvise replacement doses.

The exact plan must be checked for both formulations, the dispensing route and administration site. Also ask about visits and laboratory charges. Another person’s approval or copay is not a reliable estimate of yours.

Yeztugo was highly effective in the PURPOSE trials, but protection is not guaranteed. At the primary analysis, PURPOSE 1 recorded no HIV infections among 2,134 participants receiving Yeztugo. PURPOSE 2 recorded two among 2,179. In PURPOSE 2, the reduction was 96% compared with estimated background HIV incidence and 89% compared with daily Truvada. Those comparisons are different. Additional infections were found after the primary analyses. Complete initiation, on-time injections and HIV testing remain essential, even when trial results show very high protection.

Yeztugo is a Gilead Sciences medicine. Its active ingredient is lenacapavir. The manufacturer name does not confirm that a particular clinic has Yeztugo available.

The FDA approved Yeztugo for HIV pre-exposure prophylaxis on June 18, 2025. The approved use is to reduce sexually acquired HIV-1 risk in adults and adolescents weighing at least 35 kg who do not have HIV. The current continuation schedule is every 26 weeks, with a two-week window on either side. This approval does not establish approval of a once-yearly injection or a standalone weekly-pill prevention regimen.

No. Yeztugo is an antiretroviral medicine for HIV pre-exposure prophylaxis. Lenacapavir blocks steps in HIV replication by acting on the viral capsid. You must be HIV-negative before starting and before each injection. Scheduled doses and ongoing testing are required. It does not treat established HIV by itself or prevent other sexually transmitted infections.

Yeztugo is lenacapavir for prevention of sexually acquired HIV-1 in people who do not have HIV. Treatment starts with injections and tablets, then continues with injections about every six months. It can suit someone who prefers fewer medication visits, provided testing and follow-up remain reliable. Twice-yearly medication does not mean twice-yearly attention to every health concern: a new exposure, symptoms, STI screening or a medication change can require contact sooner. The time to maximal protection after initiation is unknown. Complete the required initiation and ask the clinician what additional prevention is appropriate during the start or switch. Do not assume immediate complete protection from an injection.